CeleCor Therapeutics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1155 Camino del Mar PMB 481, Del Mar, Ca...Phone Number
(858) 777-9750Website
www.celecor.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About CeleCor Therapeutics
CeleCor Therapeutics focuses on improving the treatment of ST-Segment Elevated Myocardial Infarctions (STEMI heart attacks) at the first point of medical contact. Their primary product, zalunfiban, is an investigational next-generation GPIIb/IIIa platelet inhibitor designed for rapid pre-hospital treatment of heart attacks. The company aims to address the time-to-treatment gap, potentially enhancing outcomes for patients experiencing acute myocardial infarctions. CeleCor Therapeutics targets healthcare providers and emergency medical services involved in the treatment of heart attack patients.Explore more
CeleCor Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CeleCor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if CeleCor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when CeleCor Therapeutics launches new products
Click to see if CeleCor Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at CeleCor Therapeutics
Check out if CeleCor Therapeutics is spiking on competitors!
Earning: See what the market has to say on CeleCor Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
CeleCor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once CeleCor Therapeutics has new funding data
Recommended Actions
Find VP level buyers at CeleCor Therapeutics
Find 3 more new buyers
Compare Similar Companies to CeleCor Therapeutics
Compare insights from companies similar to CeleCor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CeleCor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CeleCor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CeleCor Therapeutics.
CeleCor Therapeutics financials insights
Gather financial insights about CeleCor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$11.9M
CeleCor Therapeutics Tech Stack
A closer look at the technologies used by CeleCor Therapeutics
CeleCor Therapeutics News & Media
CeleCor Announces Publication of Positive Clinical Results of RUC-4, a Novel Second Generation Platelet GPIIb/IIIa Inhibitor Designed for Subcutaneous Point-of-Care STEMI Therapy
SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. announced positive clinical results of RUC-4 which was published in the Journal of the American Heart Association.CORRECTING and REPLACING Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science Session
SAN DIEGO--(BUSINESS WIRE)--Data from a completed clinical study show RUC-4 provided a potent, rapid, and sustained platelet inhibition effect in stable CAD patients w/aspirin.Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science Session
SAN DIEGO--(BUSINESS WIRE)--Data from a completed clinical study show RUC-4 provided a potent, rapid, and sustained platelet inhibition effect in stable CAD patients w/aspirin.CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019
SAN DIEGO--(BUSINESS WIRE)-- #TCT2019--FIH data shows that RUC-4, a novel subcutaneous platelet GPIIb/IIIa inhibitor, resulted in a potent, rapid, and sustained platelet inhibition effect.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CeleCor Therapeutics
Sign Up For FreeTo access detailed company insights
CeleCor Therapeutics focuses on improving the treatment of ST-Segment Elevated Myocardial Infarctions (STEMI heart attacks) at the first point of medical contact. Their primary product, zalunfiban, is an investigational next-generation GPIIb/IIIa platelet inhibitor designed for rapid pre-hospital treatment of heart attacks. The company aims to addr... Read More
